The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders
Open accessAbstract
BACKGROUND/AIMS: Hepatocellular carcinoma (HCC) is a common malignant tumour worldwide, and its differential diagnosis from benign lesions of the liver is often difficult yet of great clinical importance. In the present study, we analysed whether glypican-3 is useful in differentiating between benign and malignant liver diseases and whether it influences the growth behaviour of HCC. METHODS: Northern blot analysis and in situ hybridisation. RESULTS: Northern blot analysis indicated that expression of glypican-3 mRNA was either low or absent in normal liver, in focal nodular hyperplasia (FNH), and in liver cirrhosis. In contrast, expression of glypican-3 mRNA was markedly increased in 20 of 30 and moderately increased in five of 30 HCC samples. The average increase in glypican-3 mRNA expression in HCC was significant compared with expression in normal liver (21.7-fold increase, p<0.01). In comparison with FNH or liver cirrhosis, glypican-3 mRNA expression in HCC was increased 7.2- (p<0.05) and 10.8-fold (p<0.01), respectively. In addition, pushing HCCs exhibited significantly higher glypican-3 mRNA expression than invading tumours (p<0.05). In situ hybridisation analysis demonstrated weak expression of glypican-3 mRNA in normal hepatocytes and bile ductular cells, and weak to occasionally moderate signals in hepatocytes forming nodules of liver cirrhosis and in regenerated hepatic nodules of FNH. In contrast, glypican-3 in situ hybridisation signals were intense in hepatic cancer cells with even higher levels in pushing HCCs than in invading HCCs. CONCLUSIONS: These findings suggest that glypican-3, in many cases, has the potential to differentiate between benign and malignant liver diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TNM Classification of Malignant Tumours
(1987) · Springer eBooks · doi:10.1007/978-3-642-82982-6 · Cited by 16,049
Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome
Pilia, G., Hughes-Benzie, R. M., MacKenzie, A., Baybayan, P., Chen, E. Y., Huber, R., Neri, G., Cao, A., Forabosco, A., & Schlessinger, D. (1996) · Nature Genetics · doi:10.1038/ng0396-241 · Cited by 761
Kleeff, J., Ishiwata, T., Kumbasar, A., Friess, H., Büchler, M. W., Lander, A. D., & Korc, M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci4105 · Cited by 368
Self-citation(1997) · PubMed · Cited by 239
Ueki, T., Fujimoto, J., Suzuki, T., Yamamoto, H., & Okamoto, E. (1997) · Hepatology · doi:10.1002/hep.510250413 · Cited by 226
Gonzalez, A. D., Kaya, M., Shi, W., Song, H., Testa, J. R., Penn, L. Z., & Filmus, J. (1998) · The Journal of Cell Biology · doi:10.1083/jcb.141.6.1407 · Cited by 181
Frequent silencing of the GPC3 gene in ovarian cancer cell lines.
Lin, H. J., Huber, R., Schlessinger, D., & Morin, P. J. (1999) · PubMed · Cited by 170
Expression of GPC3, an X-linked recessive overgrowth gene, is silenced in malignant mesothelioma
Murthy, S. S., Shen, T., Rienzo, A. D., Lee, W.-C., Ferriola, P. C., Jhanwar, S. C., Mossman, B. T., Filmus, J., & Testa, J. R. (2000) · Oncogene · doi:10.1038/sj.onc.1203322 · Cited by 150
bax , but not bcl-2 , influences the prognosis of human pancreatic cancer
Friess, H., Zhao, L., Graber, H. U., Zimmermann, A., Adler, G., Korc, M., Schmid, R. M., & Büchler, M. W. (1998) · Gut · doi:10.1136/gut.43.3.414 · Cited by 134
Self-citationGpc3 expression correlates with the phenotype of the Simpson-Golabi-Behmel syndrome
Pellegrini, M., Pilia, G., Pantano, S., Lucchini, F., Uda, M., Fumi, M., Cao, A., Schlessinger, D., & Forabosco, A. (1998) · Developmental Dynamics · doi:10.1002/(sici)1097-0177(199812)213:4<431::aid-aja8>3.0.co;2-7 · Cited by 110
Cited by
Omata, M., Cheng, A.-L., Kokudo, N., Kudo, M., Lee, J. M., Jia, J., Tateishi, R., Han, K.-H., Chawla, Y. K., Shiina, S., et al. (2017) · Hepatology International · doi:10.1007/s12072-017-9799-9 · Cited by 2,171
Omata, M., Lesmana, L. A., Tateishi, R., Chen, P.-J., Lin, S.-M., Yoshida, H., Kudo, M., Lee, J. M., Choi, B. I., Poon, R. T. P., et al. (2010) · Hepatology International · doi:10.1007/s12072-010-9165-7 · Cited by 1,026
Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma
Capurro, M., Wanless, I. R., Sherman, M., Deboer, G., Shi, W., Miyoshi, E., & Filmus, J. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00689-9 · Cited by 917
Glypican-3 Promotes the Growth of Hepatocellular Carcinoma by Stimulating Canonical Wnt Signaling
Capurro, M. I., Xiang, Y.-Y., Lobe, C., & Filmus, J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4244 · Cited by 469
Glypican-3 as a Serum Marker for Hepatocellular Carcinoma
Capurro, M., & Filmus, J. (2005) · Cancer Research · doi:10.1158/0008-5472.372.65.1 · Cited by 432
Metadata
- Authors
- Zhu, Z.-W., Friess, H., Wang, L., Abou-Shady, M., Zimmermann, A., Lander, A. D., Korc, M., Kleeff, J., & Büchler, M. W.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2001-04-01
- Volume
- 48
- Issue
- 4
- Pages
- 558-564
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2049388096
- Cited by
- 291
- References
- 14
- FWCI
- 4.04
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. https://app.cochat.ai/papers/10.1136/gut.48.4.558
- The paper
- Zhu, Z.-W., Friess, H., Wang, L., Abou-Shady, M., Zimmermann, A., Lander, A. D., Korc, M., Kleeff, J., & Büchler, M. W. (2001). Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut. https://doi.org/10.1136/gut.48.4.558
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.